As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a ...
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD ...
As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial ...
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid ...
Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and ...
The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's ...
AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in ...
Detailed price information for Cullinan Therapeutics Inc (CGEM-Q) from The Globe and Mail including charting and trades.
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026Reported glioblastoma (GBM) data showing ~97% ...
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in ...
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen ...
Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results